The encephalomyelitis market size has grown strongly in recent years. It will grow from $22.58 billion in 2025 to $24.08 billion in 2026 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to neurological disease prevalence, autoimmune disorder recognition, diagnostic imaging access, specialist neurology growth, hospital neurology departments.
The encephalomyelitis market size is expected to see strong growth in the next few years. It will grow to $30.84 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to advanced immunotherapies, early diagnosis programs, neurological rehabilitation demand, research into rare neurological diseases, healthcare infrastructure growth. Major trends in the forecast period include growing awareness of neuroinflammatory disorders, increased diagnosis of autoimmune neurological conditions, rising demand for long-term neurological care, expansion of immunomodulatory treatment approaches, focus on early neurological intervention.
The increasing prevalence of autoimmune diseases is anticipated to drive the growth of the encephalomyelitis market in the coming years. Autoimmune diseases are conditions in which the immune system mistakenly attacks the body’s own healthy cells and tissues. The rise in these diseases is linked to factors such as genetic susceptibility, environmental influences, infections, and lifestyle changes, including diet and chemical exposure. Encephalomyelitis treatments help autoimmune disease patients by reducing inflammation, regulating immune system dysfunction, relieving neurological symptoms, and slowing disease progression, thereby improving overall quality of life and functional outcomes. For example, in February 2024, Arthritis Australia, an Australia-based non-profit organization, reported that in 2025 an estimated 212,136 males and 362,137 females are expected to be living with rheumatoid arthritis (RA), with projections indicating an increase by 2040 to around 280,040 males and 479,828 females. Thus, the rising burden of autoimmune diseases is contributing to the expansion of the encephalomyelitis market.
Leading companies in the encephalomyelitis market are concentrating on the development of advanced monoclonal antibody therapies to improve treatment effectiveness and enable more targeted approaches for managing encephalomyelitis. Monoclonal antibodies are laboratory-engineered proteins designed to bind to specific antigens and support the immune response against disease. For instance, in March 2023, Chugai Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, announced that its humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, Enspryng, received forerunner designation from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its potential use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and autoimmune encephalitis (AIE). This designation highlights Enspryng’s promise as an innovative therapy and accelerates its development and regulatory review to address unmet needs in patients with these neurological disorders.
In January 2024, Zuellig Pharma Holdings Ltd., a Singapore-based healthcare and hospital services company, entered into a partnership with Substipharm Biologics. This collaboration aims to enhance the availability of the IMOJEV Japanese encephalitis vaccine across nine Asian markets by leveraging Zuellig Pharma’s marketing and distribution capabilities along with ZP Therapeutics’ expertise. Substipharm Biologics is a France-based pharmaceutical company that develops a range of vaccines, including those for encephalitis and encephalomyelitis.
Major companies operating in the encephalomyelitis market are Merck & Co. Inc., Sanofi S.A., F. Hoffmann-La Roche Ltd., HiFiBiO Therapeutics, Zoetis Services LLC, Chugai Pharmaceutical Co. Ltd., IDEXX, Abcam Limited., EUROIMMUN Medizinische Labordiagnostika AG, Eurogentec S.A., Boehringer Ingelheim International GmbH, Creative Diagnostics, Atlas Antibodies, AnaSpec, VMRD Inc., Antibodies Incorporated, Fresenius Kabi, Hemispherx Biopharma Inc., BioStoneah, YouSeq Ltd.
North America was the largest region in the encephalomyelitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the encephalomyelitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the encephalomyelitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the encephalomyelitis market by increasing costs of imported diagnostic tools, immunotherapies, and neurological treatment equipment. Hospitals and specialty clinics in developed regions are most affected due to reliance on imported medical technologies. These tariffs increase treatment costs by raising expenses for advanced diagnostics and long-term disease management, affecting patient access to care. However, they encourage domestic medical innovation, fostering regional development of neurological diagnostics and therapies.
The encephalomyelitis market research report is one of a series of new reports that provides encephalomyelitis market statistics, including encephalomyelitis industry global market size, regional shares, competitors with a encephalomyelitis market share, detailed encephalomyelitis market segments, market trends and opportunities, and any further data you may need to thrive in the encephalomyelitis industry. This encephalomyelitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Encephalomyelitis is a condition characterized by inflammation of both the brain and the spinal cord, typically caused by infections, immune system dysfunction, or other underlying medical conditions. This disorder leads to a range of neurological complications, including muscle weakness, paralysis, and cognitive impairments.
The primary types of encephalomyelitis include equine encephalomyelitis, associated encephalomyelitis, anti-myelin oligodendrocyte glycoprotein antibody (anti-MOG) encephalomyelitis, encephalomyelitis disseminata, acute disseminated encephalomyelitis, AIDS-related encephalomyelitis, and others. Equine encephalomyelitis is a viral illness affecting horses, caused by eastern, western, or Venezuelan equine encephalitis viruses, which lead to inflammation of the brain and spinal cord. Available treatment approaches include surgery, plasmapheresis, drug therapy, and others, and these treatments are delivered across various end users such as hospitals, clinics, and other healthcare settings.
The encephalomyelitis market consists of revenues earned by entities by providing services such as chest X-rays and CT scans, rapid diagnostic tests, sputum cultures, and blood cultures. The market value includes the value of related goods sold by the service provider or included within the service offering. The encephalomyelitis market also includes sales of antiviral therapy, and corticosteroids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The encephalomyelitis market size is expected to see strong growth in the next few years. It will grow to $30.84 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to advanced immunotherapies, early diagnosis programs, neurological rehabilitation demand, research into rare neurological diseases, healthcare infrastructure growth. Major trends in the forecast period include growing awareness of neuroinflammatory disorders, increased diagnosis of autoimmune neurological conditions, rising demand for long-term neurological care, expansion of immunomodulatory treatment approaches, focus on early neurological intervention.
The increasing prevalence of autoimmune diseases is anticipated to drive the growth of the encephalomyelitis market in the coming years. Autoimmune diseases are conditions in which the immune system mistakenly attacks the body’s own healthy cells and tissues. The rise in these diseases is linked to factors such as genetic susceptibility, environmental influences, infections, and lifestyle changes, including diet and chemical exposure. Encephalomyelitis treatments help autoimmune disease patients by reducing inflammation, regulating immune system dysfunction, relieving neurological symptoms, and slowing disease progression, thereby improving overall quality of life and functional outcomes. For example, in February 2024, Arthritis Australia, an Australia-based non-profit organization, reported that in 2025 an estimated 212,136 males and 362,137 females are expected to be living with rheumatoid arthritis (RA), with projections indicating an increase by 2040 to around 280,040 males and 479,828 females. Thus, the rising burden of autoimmune diseases is contributing to the expansion of the encephalomyelitis market.
Leading companies in the encephalomyelitis market are concentrating on the development of advanced monoclonal antibody therapies to improve treatment effectiveness and enable more targeted approaches for managing encephalomyelitis. Monoclonal antibodies are laboratory-engineered proteins designed to bind to specific antigens and support the immune response against disease. For instance, in March 2023, Chugai Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, announced that its humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, Enspryng, received forerunner designation from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its potential use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and autoimmune encephalitis (AIE). This designation highlights Enspryng’s promise as an innovative therapy and accelerates its development and regulatory review to address unmet needs in patients with these neurological disorders.
In January 2024, Zuellig Pharma Holdings Ltd., a Singapore-based healthcare and hospital services company, entered into a partnership with Substipharm Biologics. This collaboration aims to enhance the availability of the IMOJEV Japanese encephalitis vaccine across nine Asian markets by leveraging Zuellig Pharma’s marketing and distribution capabilities along with ZP Therapeutics’ expertise. Substipharm Biologics is a France-based pharmaceutical company that develops a range of vaccines, including those for encephalitis and encephalomyelitis.
Major companies operating in the encephalomyelitis market are Merck & Co. Inc., Sanofi S.A., F. Hoffmann-La Roche Ltd., HiFiBiO Therapeutics, Zoetis Services LLC, Chugai Pharmaceutical Co. Ltd., IDEXX, Abcam Limited., EUROIMMUN Medizinische Labordiagnostika AG, Eurogentec S.A., Boehringer Ingelheim International GmbH, Creative Diagnostics, Atlas Antibodies, AnaSpec, VMRD Inc., Antibodies Incorporated, Fresenius Kabi, Hemispherx Biopharma Inc., BioStoneah, YouSeq Ltd.
North America was the largest region in the encephalomyelitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the encephalomyelitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the encephalomyelitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the encephalomyelitis market by increasing costs of imported diagnostic tools, immunotherapies, and neurological treatment equipment. Hospitals and specialty clinics in developed regions are most affected due to reliance on imported medical technologies. These tariffs increase treatment costs by raising expenses for advanced diagnostics and long-term disease management, affecting patient access to care. However, they encourage domestic medical innovation, fostering regional development of neurological diagnostics and therapies.
The encephalomyelitis market research report is one of a series of new reports that provides encephalomyelitis market statistics, including encephalomyelitis industry global market size, regional shares, competitors with a encephalomyelitis market share, detailed encephalomyelitis market segments, market trends and opportunities, and any further data you may need to thrive in the encephalomyelitis industry. This encephalomyelitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Encephalomyelitis is a condition characterized by inflammation of both the brain and the spinal cord, typically caused by infections, immune system dysfunction, or other underlying medical conditions. This disorder leads to a range of neurological complications, including muscle weakness, paralysis, and cognitive impairments.
The primary types of encephalomyelitis include equine encephalomyelitis, associated encephalomyelitis, anti-myelin oligodendrocyte glycoprotein antibody (anti-MOG) encephalomyelitis, encephalomyelitis disseminata, acute disseminated encephalomyelitis, AIDS-related encephalomyelitis, and others. Equine encephalomyelitis is a viral illness affecting horses, caused by eastern, western, or Venezuelan equine encephalitis viruses, which lead to inflammation of the brain and spinal cord. Available treatment approaches include surgery, plasmapheresis, drug therapy, and others, and these treatments are delivered across various end users such as hospitals, clinics, and other healthcare settings.
The encephalomyelitis market consists of revenues earned by entities by providing services such as chest X-rays and CT scans, rapid diagnostic tests, sputum cultures, and blood cultures. The market value includes the value of related goods sold by the service provider or included within the service offering. The encephalomyelitis market also includes sales of antiviral therapy, and corticosteroids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Encephalomyelitis Market Characteristics
3. Encephalomyelitis Market Supply Chain Analysis
4. Global Encephalomyelitis Market Trends and Strategies
5. Encephalomyelitis Market Analysis of End Use Industries
7. Global Encephalomyelitis Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Encephalomyelitis Total Addressable Market (TAM) Analysis for the Market
9. Encephalomyelitis Market Segmentation
10. Encephalomyelitis Market Regional and Country Analysis
11. Asia-Pacific Encephalomyelitis Market
12. China Encephalomyelitis Market
13. India Encephalomyelitis Market
14. Japan Encephalomyelitis Market
15. Australia Encephalomyelitis Market
16. Indonesia Encephalomyelitis Market
17. South Korea Encephalomyelitis Market
18. Taiwan Encephalomyelitis Market
19. South East Asia Encephalomyelitis Market
20. Western Europe Encephalomyelitis Market
21. UK Encephalomyelitis Market
22. Germany Encephalomyelitis Market
23. France Encephalomyelitis Market
24. Italy Encephalomyelitis Market
25. Spain Encephalomyelitis Market
26. Eastern Europe Encephalomyelitis Market
27. Russia Encephalomyelitis Market
28. North America Encephalomyelitis Market
29. USA Encephalomyelitis Market
30. Canada Encephalomyelitis Market
31. South America Encephalomyelitis Market
32. Brazil Encephalomyelitis Market
33. Middle East Encephalomyelitis Market
34. Africa Encephalomyelitis Market
36. Encephalomyelitis Market Competitive Landscape and Company Profiles
37. Encephalomyelitis Market Other Major and Innovative Companies
40. Encephalomyelitis Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Encephalomyelitis Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses encephalomyelitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for encephalomyelitis? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The encephalomyelitis market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Equine Encephalomyelitis; Associated Encephalomyelitis; Anti-Myelin Oligodendrocyte Glycoprotein Antibody (AntiMOG); Encephalomyelitis Disseminata; Acute Disseminated Encephalomyelitis; AIDS-Related Encephalomyelitis; Other Types2) By Treatment: Surgery; Plasmapheresis; Drug Treatment; Other Treatments
3) By End-users: Clinics; Hospitals; Other End-Users
Subsegments:
1) By Equine Encephalomyelitis: Eastern Equine Encephalomyelitis; Western Equine Encephalomyelitis; Venezuelan Equine Encephalomyelitis2) By Associated Encephalomyelitis: Post-Infectious Encephalomyelitis; Paraneoplastic Encephalomyelitis; Vaccine-Associated Encephalomyelitis
3) By Anti-Myelin Oligodendrocyte Glycoprotein Antibody (AntiMOG): MOG Antibody-Positive Encephalomyelitis; MOG Antibody-Associated Neuromyelitis Optica Spectrum Disorder
4) By Encephalomyelitis Disseminata: Multiple Sclerosis-Related Encephalomyelitis; Relapsing-Remitting Encephalomyelitis Disseminata; Progressive Encephalomyelitis Disseminata
5) By Acute Disseminated Encephalomyelitis: Post-Viral Acute Disseminated Encephalomyelitis; Post-Vaccination Acute Disseminated Encephalomyelitis
6) By AIDS-Related Encephalomyelitis: HIV-Associated Encephalomyelitis; Opportunistic Infection-Related Encephalomyelitis; Other AIDS-Related Encephalomyelitis
7) By Other Types: Idiopathic Encephalomyelitis; Autoimmune Encephalomyelitis; Rare Genetic Encephalomyelitis Variants
Companies Mentioned: Merck & Co. Inc.; Sanofi S.A.; F. Hoffmann-La Roche Ltd.; HiFiBiO Therapeutics; Zoetis Services LLC; Chugai Pharmaceutical Co. Ltd.; IDEXX; Abcam Limited.; EUROIMMUN Medizinische Labordiagnostika AG; Eurogentec S.A.; Boehringer Ingelheim International GmbH; Creative Diagnostics; Atlas Antibodies; AnaSpec; VMRD Inc.; Antibodies Incorporated; Fresenius Kabi; Hemispherx Biopharma Inc.; BioStoneah; YouSeq Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Encephalomyelitis market report include:- Merck & Co. Inc.
- Sanofi S.A.
- F. Hoffmann-La Roche Ltd.
- HiFiBiO Therapeutics
- Zoetis Services LLC
- Chugai Pharmaceutical Co. Ltd.
- IDEXX
- Abcam Limited.
- EUROIMMUN Medizinische Labordiagnostika AG
- Eurogentec S.A.
- Boehringer Ingelheim International GmbH
- Creative Diagnostics
- Atlas Antibodies
- AnaSpec
- VMRD Inc.
- Antibodies Incorporated
- Fresenius Kabi
- Hemispherx Biopharma Inc.
- BioStoneah
- YouSeq Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 24.08 Billion |
| Forecasted Market Value ( USD | $ 30.84 Billion |
| Compound Annual Growth Rate | 6.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
